TNF-α has been widely used in vitro studies to elicit pro-inflammatory conditions as observed in hypertension and cardiovascular diseases [42], and as such, TNF-α co-treatment of endothelial cells, along with S1, was used to mimic pre-existing cardiovascular comorbidity in the setting of COVID-19. Here, TNF is linked to cardiovascular disorder.